+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

SU5416 sensitizes ovarian cancer cells to cisplatin through inhibition of nucleotide excision repair



SU5416 sensitizes ovarian cancer cells to cisplatin through inhibition of nucleotide excision repair



CMLS Cellular & Molecular Life Sciences 60(4): 794-802



SU5416 is reported to be a selective inhibitor of vascular endothelial growth factor, and it has metwith limited success in the clinic. In the present study, we investigated whether SU5416 could augment cisplatin-induced cytotoxicity in human ovarian cancer cells. When used as a single agent, 2-h exposures to SU5416 were not harmful to the cells up to doses of 100 microM. For 48-h exposures, the SU5416 IC20 and IC50 were 17 and 34 microM, respectively. When used with cisplatin, the effect of SU5416 was sequence dependent. SU5416 given first was subadditive, whereas cisplatin given first was supraadditive. Cisplatin was given as a 1-h exposure. Augmented cisplatin cytotoxicity was seen with 2-h exposures to SU5416 at doses of 17-34 microM. This was associated with a decrease in cisplatin-DNA adduct repair, as measured by atomic absorbance spectrometry. Treatment of the ovarian carcinoma cells with SU5416 was also associated with a reduced expression of ERCC-1 protein and c-jun mRNA, as well as a decrease in c-Jun and JNK activities. We conclude that SU5416 can be used to augment cisplatin-induced cell killing at doses that are non-toxic. This effect may occur through direct or indirect reduction of the activity of AP-1 and DNA repair.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 011320947

Download citation: RISBibTeXText

PMID: 12785726

DOI: 10.1007/s00018-003-3002-2


Related references

Increased nucleotide excision repair in cisplatin-resistant ovarian cancer cells: Role of ERCC1-XPF. Biochemical Pharmacology 60(9): 1305-1313, 1 November, 2000

Enhanced cisplatin cytotoxicity by disturbing the nucleotide excision repair pathway in a cisplatin resistant ovarian cancer cell line. Proceedings of the American Association for Cancer Research Annual Meeting 42: 813, 2001

Differential contributory roles of nucleotide excision and homologous recombination repair for enhancing cisplatin sensitivity in human ovarian cancer cells. Molecular Cancer 10: 24, 2011

Relationship between nucleotide excision repair gene ERCC1 and resistance to cisplatin in ovarian cancer. Zhonghua Zhong Liu Za Zhi 30(3): 184-187, 2008

Enhanced cisplatin cytotoxicity by disturbing the nucleotide excision repair pathway in ovarian cancer cell lines. Cancer Research 63(6): 1311-1316, 2003

Inhibition of the CSF-1 receptor sensitizes ovarian cancer cells to cisplatin. Cell Biochemistry and Function 36(2): 80-87, 2018

Noscapine sensitizes chemoresistant ovarian cancer cells to cisplatin through inhibition of HIF-1α. Cancer Letters 305(1): 94-99, 2011

Inhibition of AKT sensitizes chemoresistant ovarian cancer cells to cisplatin by abrogating S and G2/M arrest. Experimental and Molecular Pathology 100(3): 506-513, 2016

Malondialdehyde, a major endogenous lipid peroxidation product, sensitizes human cells to UV- and BPDE-induced killing and mutagenesis through inhibition of nucleotide excision repair. Mutation Research 601(1-2): 125-136, 2006

Inhibition of phosphorylation of a forkhead transcription factor sensitizes human ovarian cancer cells to cisplatin. Endocrinology 145(4): 2014-2022, 2004

Time-staggered inhibition of JNK effectively sensitizes chemoresistant ovarian cancer cells to cisplatin and paclitaxel. Oncology Reports 35(1): 593-601, 2016

Effect of taxol and cisplatin on the expression of excision repair genes in human ovarian cancer cells. Proceedings of the American Association for Cancer Research Annual Meeting 34: 357, 1993

Expression of the DNA Nucleotide Excision Repair Gene ERCC1 in Lung Cancer Cells Relationship to Acquired and Intrinsic Resistance to Cisplatin. Proceedings of the American Association for Cancer Research Annual Meeting 36: 357, 1995

Nucleotide excision repair in the human ovarian carcinoma cell line and its cisplatin-resistant variant. Proceedings of the American Association for Cancer Research Annual Meeting 36: 140, 1995

Rad6 inhibition sensitizes ovarian cancer cells to platinum drugs by attenuating activation of multiple DNA repair networks. Gynecologic Oncology 141: 67-68, 2016